with the intention of outcompeting the mutated β-sickle chains and increasing fetal hemoglobin formation. Comparative studies of vector encoding γ(G16D) versus unmodified γ-globin show a higher ...

“In this therapy, we do not change or edit the genes that cause sickle cell disease,” Kanter says. “Instead, we use a viral vector to deliver a new gene that will make a healthy hemoglobin—a beta ...

Next, they transduced CD34 + cells obtained from the cord blood of newborns with sickle cell disease. The cells were transduced with a lentiviral vector delivering the gene encoding the anti ...

The primary purpose of this study is to evaluate the efficacy and safety of treatment with LentiGlobin BB305 Drug Product and autologous transplant in individuals with severe sickle cell disease (SCD) ...

The new "SICKLE-VS6D" operates at the maximum number of frequencies from all complexes of the "SICKLE" line, developed by engineers of the Research Institute "Vector" of the holding "Roselektronika".

The US biotech said the suspected serious adverse reaction reported in the phase 1/2 study of LentiGlobin gene therapy for sickle cell disease was unlikely to be related to the virus vector used ...

no vector-related complications, and no insertional oncogenesis. For complete safety information please refer to the U.S. Prescribing Information noted below. Data from patients with sickle cell ...